- Home
- Publications
- Publication Search
- Publication Details
Title
Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)
Authors
Keywords
-
Journal
Biomedicines
Volume 9, Issue 5, Pages 445
Publisher
MDPI AG
Online
2021-04-22
DOI
10.3390/biomedicines9050445
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effectiveness and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients with Acute Venous Thromboembolism
- (2020) James C. Coons et al. PHARMACOTHERAPY
- Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation
- (2020) Marina Serper et al. HEPATOLOGY
- Assessment of direct oral anticoagulant assay use in clinical practice
- (2019) Tina M. Gu et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Prothrombin times in the presence of edoxaban - in-vivo experience from King's College hospital
- (2018) Jignesh P. Patel et al. BRITISH JOURNAL OF HAEMATOLOGY
- International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
- (2018) Robert Gosselin et al. THROMBOSIS AND HAEMOSTASIS
- Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
- (2018) Konstantinos N. Aronis et al. Journal of the American Heart Association
- Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis
- (2018) Matthias Ebner et al. Journal of the American Heart Association
- Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice
- (2017) C. Wright et al. International Journal of Laboratory Hematology
- To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply
- (2017) A. Tripodi JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
- (2017) Charles V. Pollack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa
- (2016) Blisse Vakkalagadda et al. American Journal of Cardiovascular Drugs
- Antithrombotic Therapy for VTE Disease
- (2016) Clive Kearon et al. CHEST
- Urgent Need to Measure Effects of Direct Oral Anticoagulants: Table.
- (2016) Jeffrey I. Weitz et al. CIRCULATION
- Estimation of Rivaroxaban Plasma Concentrations in the Perioperative Setting in Patients With or Without Heparin Bridging
- (2016) Sarah Lessire et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery
- (2016) A. C. Spyropoulos et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
- (2016) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Direct oral anticoagulant drug level testing in clinical practice: A single institution experience
- (2016) Karlyn Martin et al. THROMBOSIS RESEARCH
- An update on laboratory measurements of Dabigatran: Smart specific and calibrated dedicated assays for measuring anti-IIa activity in plasma
- (2016) Jean Amiral et al. TRANSFUSION AND APHERESIS SCIENCE
- Laboratory measurement of the direct oral anticoagulants
- (2015) Brian J. Dale et al. BRITISH JOURNAL OF HAEMATOLOGY
- Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?
- (2015) Giuseppe Lippi et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
- (2015) Jeanne Mendell et al. CLINICAL DRUG INVESTIGATION
- Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials
- (2015) C. Chai-Adisaksopha et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
- (2015) Christian T Ruff et al. LANCET
- Measurement of dabigatran plasma concentrations by calibrated thrombin clotting time in comparison to LC-MS/MS in human volunteers on dialysis
- (2015) Michael Schmohl et al. THROMBOSIS RESEARCH
- A proposal for dose-adjustment of dabigatran etexilate in atrial fibrillation guided by thrombin time
- (2014) Paul K. L. Chin et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Normal prothrombin times in the presence of therapeutic levels of apixaban -in-vivoexperience from King's College Hospital
- (2014) Jignesh P. Patel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Measurement of non-Coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology
- (2014) Steve Kitchen et al. BRITISH JOURNAL OF HAEMATOLOGY
- Direct Oral Anticoagulants
- (2014) Jerrold H. Levy et al. JACC-Cardiovascular Interventions
- Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
- (2014) Adam Cuker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation
- (2014) Mika Skeppholm et al. THROMBOSIS RESEARCH
- Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor
- (2013) Jeanne Mendell et al. American Journal of Cardiovascular Drugs
- Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects
- (2013) Vijay V. Upreti et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects
- (2013) Charles Frost et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
- (2013) Wolfgang Mueck et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban - early experience from King's College Hospital
- (2013) Jignesh P. Patel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
- (2013) S. J. Connolly et al. EUROPEAN HEART JOURNAL
- The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients
- (2013) Paul A. Reilly et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
- (2013) Christian T Ruff et al. LANCET
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
- (2012) Charles Frost et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study
- (2012) Joel Morganroth et al. EXPERT OPINION ON PHARMACOTHERAPY
- Impact of dabigatran on a large panel of routine or specific coagulation assays
- (2012) Séverine Robert et al. THROMBOSIS AND HAEMOSTASIS
- Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects
- (2012) Nobuko Matsushima et al. THROMBOSIS AND HAEMOSTASIS
- Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor
- (2011) Kan He et al. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
- (2011) M. J. Gnoth et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
- (2010) Koichiro Ogata et al. JOURNAL OF CLINICAL PHARMACOLOGY
- An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma
- (2010) Jean Amiral et al. THROMBOSIS AND HAEMOSTASIS
- Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay
- (2010) Zhaoqing Wang et al. THROMBOSIS AND HAEMOSTASIS
- Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
- (2010) Jean-Luc Martinoli et al. THROMBOSIS AND HAEMOSTASIS
- Mass Spectrometry in the Clinical Laboratory: How Have We Done, and Where Do We Need to Be?
- (2009) T. Annesley CLINICAL CHEMISTRY
- Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects
- (2009) Joachim Stangier et al. CLINICAL PHARMACOKINETICS
- Metabolism and Excretion of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans
- (2009) C. Weinz et al. DRUG METABOLISM AND DISPOSITION
- In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies
- (2009) L. Wang et al. DRUG METABOLISM AND DISPOSITION
- Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro
- (2009) Xiaosui Jiang et al. THROMBOSIS AND HAEMOSTASIS
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate
- (2008) Joachim Stangier CLINICAL PHARMACOKINETICS
- Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
- (2008) Bengt I Eriksson et al. CLINICAL PHARMACOKINETICS
- Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
- (2008) N. Raghavan et al. DRUG METABOLISM AND DISPOSITION
- Determination of rivaroxaban – a novel, oral, direct Factor Xa inhibitor – in human plasma by high-performance liquid chromatography–tandem mass spectrometry
- (2008) G. Rohde JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement
- (2008) Lars C. Borris et al. THROMBOSIS AND HAEMOSTASIS
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started